今日药学

1例肾脏供体来源的鲍曼不动杆菌感染治疗实践

王琴 ^1a^,² , 丁汉东 ^1b^,³^,⁴^,^*

今日药学 | 临床药学 2026,36(7): 536-539

收起

今日药学 |临床药学 2026 , 36 (7) : 536 -539

1例肾脏供体来源的鲍曼不动杆菌感染治疗实践

全屏

王琴^1a^,², 丁汉东^1b^,³^,⁴^,^*

作者信息

^1a.安徽医科大学第一附属医院，药剂科，安徽　合肥　230031

^1b.安徽医科大学第一附属医院，泌尿外科，安徽　合肥　230031

^2.国家中医药管理局中药化学三级实验室，安徽　合肥　230031

^3.安徽医科大学泌尿外科研究所，安徽　合肥　230031

^4.泌尿生殖系统疾病安徽省重点实验室，安徽　合肥　230031

通讯作者:

丁汉东，硕士，主治医师，研究方向：肾移植、器官捐献、肾脏缺血-再灌注损伤，E-mail：1005150148@qq.com

作者简介:

王琴，硕士，主管药师，研究方向：临床药学

A Case Study of Treatment Practices for Donor-Derived Acinetobacter baumannii Infection in Kidney Transplantation

Qin WANG^1a^,², Handong DING^1b^,³^,⁴^,^*

Affiliations

^1a.Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Anhui, Hefei 230031, China

^1b.Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui, Hefei 230031, China

^2.The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Anhui, Hefei 230031, China

^3.Institute of Urology, Anhui Medical University, Anhui, Hefei 230031, China

^4.Anhui Province Key Laboratory of Genitourinary Diseases, Anhui, Hefei 230031, China

出版时间: 2026-07-25 doi: 10.12048/j.issn.1674-229X.2026.07.008

文章导航

摘要

收起

目的

总结供体肾脏来源的鲍曼不动杆菌感染的治疗经验。

方法

分析1例供体来源鲍曼不动杆菌感染的治疗过程。在肾脏离体保存阶段，使用含替加环素灌注液进行持续低温灌注约10 h左右，随后进行移植。术后继续予以替加环素联合其他抗生素全身治疗6 d。治疗期间动态监测肝肾功能、淀粉酶、脂肪酶及血常规指标，定期复查尿液及引流液微生物培养。

结果

术后第3天起尿液及引流液培养连续多次均为阴性。整个治疗过程中，患者肝功能、血清淀粉酶及脂肪酶均正常，尿素及肌酐水平逐渐恢复至基本正常，未出现明显药物相关不良反应。患者于术后第22天顺利出院。

结论

在肾脏离体低温保存阶段采用含替加环素的灌注液进行离体器官预处理，联合术后短期全身抗感染治疗，能够安全、有效地清除供体来源的鲍曼不动杆菌。

关键词

肾移植 / 供者来源性感染 / 鲍曼不动杆菌 / 机械灌注 / 替加环素

Abstract

收起

OBJECTIVE

To summarize the clinical therapeutic experience in managing Acinetobacter baumannii infection originating from a kidney donor.

METHODS

A single-case analysis was conducted on the treatment of Acinetobacter baumannii infection derived from a kidney donor. During the ex vivo kidney preservation phase，the organ was continuously perfused with a tigecycline-containing solution at low temperature for approximately 10 hours，followed by transplantation. Postoperatively，systemic therapy with tigecycline combined with other antibiotics was continued for 6 days. During treatment，hepatic and renal function，serum amylase，lipase，and complete blood count (CBC) were monitored dynamically. Microbiological cultures of urine and drainage fluid were regularly repeated.

RESULTS

From postoperative day (POD) 3 onward，urine and drainage fluid cultures were repeatedly negative. Throughout the treatment period，the patient′s liver function tests，serum amylase，and lipase levels remained within normal limits. Blood urea nitrogen (BUN) and creatinine levels gradually returned to near-normal ranges. No significant drug-related adverse reactions were observed. The patient was successfully discharged on postoperative day 22.

CONCLUSION

The use of a tigecycline-containing perfusion solution during ex vivo kidney cold preservation，combined with a short-course of postoperative systemic anti-infective therapy，can safely and effectively eradicate donor-derived Acinetobacter baumannii.

Key words

kidney transplantation / donor-derived infection / Acinetobacter baumannii / mechanical perfusion / tigecycline

引用本文

王琴, 丁汉东. 1例肾脏供体来源的鲍曼不动杆菌感染治疗实践. 今日药学, 2026 , 36 (7) : 536 -539 . DOI: 10.12048/j.issn.1674-229X.2026.07.008

Qin WANG, Handong DING. A Case Study of Treatment Practices for Donor-Derived Acinetobacter baumannii Infection in Kidney Transplantation[J]. Pharmacy Today, 2026 , 36 (7) : 536 -539 . DOI: 10.12048/j.issn.1674-229X.2026.07.008

基金

收起

国家自然科学基金(82470783)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

Kaul D R, Vece G, Blumberg E, et al. Ten years of donor-derived disease: a report of the disease transmission advisory committee[J]. Am J Transplant, 2021, 21(2): 689-702.

[2]

Procaccio F, Masiero L, Vespasiano F, et al. Organ donor screening for carbapenem-resistant gram-negative bacteria in Italian intensive care units: the DRIn study[J]. Am J Transplant, 2020, 20(1): 262-273.

[3]

Tong L, Hu X G, Huang F, et al. Clinical impacts and outcomes with possible donor-derived infection in infected donor liver transplantation: a single-center retrospective study in China[J]. J Infect Dis, 2020, 221(Suppl 2): S164-S173.

[4]

Benamu E, Wolfe C R, Montoya J G. Donor-derived infections in solid organ transplant patients: toward a holistic approach[J]. Curr Opin Infect Dis, 2017, 30(4): 329-339.

[5]

Anesi J A, Blumberg E A, Han J H, et al. Impact of donor multidrug-resistant organisms on solid organ transplant recipient outcomes[J]. Transpl Infect Dis, 2022, 24(1): e13783.

[6]

Nakajima D, Cypel M, Bonato R, et al. Ex vivo perfusion treatment of infection in human donor lungs[J]. Am J Transplant, 2016, 16(4): 1229-1237.

[7]

Andreasson A, Karamanou D M, Perry J D, et al. The effect of ex vivo lung perfusion on microbial load in human donor lungs[J]. J Heart Lung Transplant, 2014, 33(9): 910-916.

[8]

Lin J W, Li Y F, Fang T D, et al. Substantial decline of organ preservation fluid contamination following adoption of ischemia-free liver transplantation: a post-hoc analysis[J]. Int J Surg, 2024, 110(5): 2855-2864.

[9]

Liang H, Zhang P, Yu B, et al. Machine perfusion combined with antibiotics prevents donor-derived infections caused by multidrug-resistant bacteria[J]. Am J Transplant, 2022, 22(7): 1791-1803.

[10]

Ison M G, Grossi P. Donor-derived infections in solid organ transplantation[J]. Am J Transplant, 2013, 13: 22-30.

[11]

中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国实体器官移植受者侵袭性真菌病临床诊治指南(2016年版)[J]. 中华器官移植杂志, 2016, 37(5): 300-305.

[12]

Murray C J L, Ikuta K S, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis[J]. The Lancet, 2022(10325): 399.

[13]

Aguado J M, Silva J T, Fernández-Ruiz M, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations[J]. Transplant Rev, 2018, 32(1): 36-57.

[14]

Bruinsma B G, Post I C J H, van Rijssen L B, et al. Antibiotic prophylaxis in (sub) normothermic organ preservation: in vitro efficacy and toxicity of cephalosporins[J]. Transplantation, 2013, 95(8): 1064-1069.

[15]

王一喆. 头孢哌酮钠舒巴坦钠在移植肾低温机械灌注中的有效性及安全性研究[D]. 新乡: 新乡医学院, 2021.

2026年第36卷第7期

引用本文

BibTeX

文章信息

doi: 10.12048/j.issn.1674-229X.2026.07.008

接收时间：2025-09-29
首发时间：2026-10-27
出版时间：2026-07-25

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-09-29

基金

国家自然科学基金(82470783)

作者信息

^1a.安徽医科大学第一附属医院，药剂科，安徽　合肥　230031

^1b.安徽医科大学第一附属医院，泌尿外科，安徽　合肥　230031

^2.国家中医药管理局中药化学三级实验室，安徽　合肥　230031

^3.安徽医科大学泌尿外科研究所，安徽　合肥　230031

^4.泌尿生殖系统疾病安徽省重点实验室，安徽　合肥　230031

通讯作者:

丁汉东，硕士，主治医师，研究方向：肾移植、器官捐献、肾脏缺血-再灌注损伤，E-mail：1005150148@qq.com

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/jryx/CN/10.12048/j.issn.1674-229X.2026.07.008

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT